11.04.2011 • NewsDaniel VasellaNovartisAlcon

Novartis Eyes Debts, Possible Smaller Buys

Swiss drugmaker Novartis will focus on its debts before undertaking any big purchases following its acquisition of eyecare group Alcon, Novartis's chairman was quoted as saying on Saturday.

The Basel-based firm spent much of last year trying to clinch 100% ownership of Alcon and has finally sealed its $50.9 billion buy by paying Alcon's minority shareholders an extra $463 million in cash.

"Now it's about cutting back on the debt burden somewhat before we can undertake new big buys," Chairman Daniel Vasella told Swiss newspaper Blick. "But smaller bolt-ons are surely still possible in the near future."

Vasella, who previously served as the firm's chief executive, also said the Alcon buy was expected to yield synergies of more than $300 million in the next three years.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.